Samsung Biologics secures first U.S. production hub in $280M deal with GSK
Samsung Biologics, the world’s leading contract development and manufacturing organization, has reached an agreement to acquire Human Genome Sciences from GSK (NYSE:GSK), marking the South Korean firm’s first physical manufacturing footprint in the United States.


-640x358.jpg&w=3840&q=75)


-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)


-1-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)